Athens, May 20, 2016
An important agreement on the promotion of the first antimicrobial thermometer into the global health market was signed on May 18, 2016, between the President and CEO of KARABINIS MEDICAL, Mr. Apostolos Karabinis, and the company MICROLIFE, a renowned leader in diagnostic health products, in the sidelines of the MICROLIFE Distributor Meeting held in Mallorca.
In January 2015, Mr. Apostolos Karabinis had presented in the frame of an official Press Conference, the Alfacheck Antimicrobial AT400, the first thermometer worldwide with antimicrobial copper. Through its technological application, patented worldwide, the Alfacheck Antimicrobial Thermometer helps to create safe thermometry conditions, not only to families but to the entire “health care chain’’ (doctors-nurses-patients)
The Press Conference had been greeted by the Health Minister at the time, who pointed out among others, the importance of innovation in the Health field, as an essential factor in the quality of life improvement as well as in the confrontation of healthcare acquired infections.
Mr. Karabinis emphasized that the signed important agreement of the antimicrobial thermometer promotion in the global health market by MICROLIFE, sealed the success of the business venture and reinforced the Greek initiative in creating innovative healthcare products through continuous scientific research, always to the benefit of human and societies in general. From now on, the antimicrobial thermometer will be available in major markets in Europe, Asia and America under Microlife brand name.
Mr. Apostolos Karabinis during his conversation with the MICROLIFE Managing Director, Mr.Jerry Lin, underlined that the signed agreement will be a landmark rapid growth, and bring huge financial benefits to both parties.